Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction inducible ischemia versus hibernating myocardium

Circulation: Cardiovascular Imaging

Volumn 6, Issue 3, 2013, Pages 363-372

  Ling, Lee Fong ^a,b   Marwick, Thomas H ^a   Flores, Demetrio Roland ^a   Jaber, Wael A ^a   Brunken, Richard C ^a   Cerqueira, Manuel D ^a   Hachamovitch, Rory ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KHOO TECK PUAT HOSPITAL   (Singapore)

Author keywords

Ischemia; Positron emission tomography; Prognosis; Revascularization; Viability

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RUBIDIUM 82; CARDIOVASCULAR AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; RUBIDIUM;

AGED; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISABILITY SEVERITY; EQUIPOISE; EUROSCORE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOCARDIAL DISEASE; MYOCARDIAL HIBERNATION; MYOCARDIUM SCAR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RACE; REVASCULARIZATION; SURVIVAL; SYSTOLIC BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CONVALESCENCE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HEART STROKE VOLUME; HEMODYNAMICS; ISCHEMIA; METHODOLOGY; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; STUNNED HEART MUSCLE; TIME; TISSUE SURVIVAL; TREATMENT OUTCOME; VIABILITY;

ISCHEMIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVASCULARIZATION; VIABILITY;

AGED; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; FLUORODEOXYGLUCOSE F18; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; MYOCARDIAL REVASCULARIZATION; MYOCARDIAL STUNNING; MYOCARDIUM; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; RUBIDIUM RADIOISOTOPES; STROKE VOLUME; TIME FACTORS; TISSUE SURVIVAL; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

MLCS; MLOWN;

EID: 84879932654     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.112.000138     Document Type: Article

References (28)

1. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151-1158. (Pubitemid 34267418)
2. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117:103-114. (Pubitemid 350301145)
3. Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: A meta-analysis. J Nucl Cardiol. 2010;17:646-654.
4. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375-410. (Pubitemid 46881171)
5. Bourque JM, Hasselblad V, Velazquez EJ, Borges-Neto S, O'connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. Am Heart J. 2003;146:621-627. (Pubitemid 37281705)
6. Bonow RO, Holly TA. Myocardial viability testing: still viable after stich? J Nucl Cardiol. 2011;18:991-994.
7. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn KY, Garrard L, deKemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko RM; PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-2012. (Pubitemid 350054917)
8. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA; STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617-1625.
9. Tarakji KG, Brunken R, McCarthy PM, Al-Chekakie MO, Abdel-Latif A, Pothier CE, Blackstone EH, Lauer MS. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation. 2006;113:230-237.
10. Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, Hayes SW, Cohen I, Germano G, Berman DS. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012-1024.
11. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351-1357. (Pubitemid 29503574)
12. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA. 2000;284:1392-1398.
13. Lauer MS, Lytle B, Pashkow F, Snader CE, Marwick TH. Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting. Lancet. 1998;351:615-622. (Pubitemid 28098443)
14. Nashef SA, Roques F, Hammill BG, Peterson ED, Michel P, Grover FL, Wyse RK, Ferguson TB; EurpSCORE Project Group. Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. Eur J Cardiothorac Surg. 2002;22:101-105. (Pubitemid 34743720)
15. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation. 1993;87:1-20. (Pubitemid 23019329)
16. Henzlova MJ, Cerqueira MD, Mahmarian JJ, Yao SS; Quality Assurance Committee of the American Society of Nuclear Cardiology. Stress protocols and tracers. J Nucl Cardiol. 2006;13:e80-e90. (Pubitemid 44913649)
17. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542. (Pubitemid 34262671)
18. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, Ficaro EP, Freeman MR, Hendel RC, Jain D, Leonard SM, Nichols KJ, Polk DM, Soman P; American Society of Nuclear Cardiology. Single photon-emission computed tomography. J Nucl Cardiol. 2010;17:941-973.
19. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107:2900-2907.
20. Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Gropler RJ, Knuuti J, Schelbert HR, Travin MI. PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol. 2009;16:651.
21. Ficaro E P, Lee BC, Kritzman JN, Corbett JR. Corridor4DM: the Michigan method for quantitative nuclear cardiology. J Nucl Cardiol. 2007;14:455-465. (Pubitemid 47163566)
22. Newman TB, Brown AN. Use of commercial record linkage software and vital statistics to identify patient deaths. J Am Med Inform Assoc. 1997;4:233-237. (Pubitemid 127431647)
23. Gottlieb SS. Dead is dead-artificial definitions are no substitute. Lancet. 1997;349:662-663. (Pubitemid 27107739)
24. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281. (Pubitemid 28466823)
25. Abraham A, Nichol G, Williams KA, Guo A, deKemp RA, Garrard L, Davies RA, Duchesne L, Haddad H, Chow B, DaSilva J, Beanlands RS; PARR 2 Investigators. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51:567-574.
26. Hage FG, Venkataraman R, Aljaroudi W, Bravo PE, McLarry J, Faulkner M, Heo J, Iskandrian AE. The impact of viability assessment using myocardial perfusion imaging on patient management and outcome. J Nucl Cardiol. 2010;17:378-389.
27. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1-194.
28. Hachamovitch R, Di Carli MF. Methods and limitations of assessing new noninvasive tests: Part II: Outcomes-based validation and reliability assessment of noninvasive testing. Circulation. 2008;117:2793-2801. (Pubitemid 351770460)